Related references
Note: Only part of the references are listed.Combination Therapy of Adalimumab With an Immunomodulator Is Not More Effective Than Adalimumab Monotherapy in Children With Crohn's Disease: A Post Hoc Analysis of the PAILOT Randomized Controlled Trial
Manar Matar et al.
INFLAMMATORY BOWEL DISEASES (2020)
Proactive Monitoring of Adalimumab Trough Concentration Associated With Increased Clinical Remission in Children With Crohn's Disease Compared With Reactive Monitoring
Amit Assa et al.
GASTROENTEROLOGY (2019)
Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study
Nicholas A. Kennedy et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2019)
The effects of concomitant immunomodulators on the pharmacokinetics, efficacy and safety of adalimumab in paediatric patients with Crohn's disease: a post hoc analysis
Jeffrey S. Hyams et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2019)
Upfront Combination Therapy, Compared With Monotherapy, for Patients Not Previously Treated With a Biologic Agent Associates With Reduced Risk of Inflammatory Bowel Disease-related Complications in a Population-based Cohort Study
Laura E. Targownik et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2019)
The Impact of Combination Therapy on Infliximab Levels and Antibodies in Children and Young Adults With Inflammatory Bowel Disease
Lisa Yue Chi et al.
INFLAMMATORY BOWEL DISEASES (2018)
Management of Paediatric Ulcerative Colitis, Part 1: Ambulatory Care-An Evidence-based Guideline From European Crohn's and Colitis Organization and European Society of Paediatric Gastroenterology, Hepatology and Nutrition
Dan Turner et al.
JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION (2018)
American Gastroenterological Association Institute Technical Review on the Role of Therapeutic Drug Monitoring in the Management of Inflammatory Bowel Diseases
Niels Vande Casteele et al.
GASTROENTEROLOGY (2017)
Infliximab Is Not Associated With Increased Risk of Malignancy or Hemophagocytic Lymphohistiocytosis in Pediatric Patients With Inflammatory Bowel Disease
Jeffrey S. Hyams et al.
GASTROENTEROLOGY (2017)
Concomitant Therapy with Immunomodulator Enhances Infliximab Durability in Pediatric Inflammatory Bowel Disease
Julianna Cheng et al.
INFLAMMATORY BOWEL DISEASES (2017)
Combination Therapy in Pediatric Inflammatory Bowel Disease: Yes, No, Maybe
Jeffrey S. Hyams et al.
INFLAMMATORY BOWEL DISEASES (2017)
Association Between Use of Thiopurines or Tumor Necrosis Factor Antagonists Alone or in Combination and Risk of Lymphoma in Patients With Inflammatory Bowel Disease
Magali Lemaitre et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2017)
Long-term outcomes of pediatric inflammatory bowel disease
Soheila Nasiri et al.
SEMINARS IN PEDIATRIC SURGERY (2017)
Trends in Epidemiology of Pediatric Inflammatory Bowel Disease in Canada: Distributed Network Analysis of Multiple Population-Based Provincial Health Administrative Databases
Eric I. Benchimol et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2017)
Infliximab and adalimumab drug levels in Crohn's disease: contrasting associations with disease activity and influencing factors
M. G. Ward et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2017)
The incidence of inflammatory bowel disease in Denmark 1980-2013: a nationwide cohort study
S. N. Lophaven et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2017)
Use of Anti-TNFα Agents and Time to First-time Surgery in Paediatric Patients with Ulcerative Colitis and Crohn's Disease
Michael Due Larsen et al.
JOURNAL OF CROHNS & COLITIS (2016)
The incidence of Crohn's disease and ulcerative colitis since 1995 in Danish children and adolescents <17 years - based on nationwide registry data
Michael Due Larsen et al.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY (2016)
Concomitant Use of Immunomodulators Affects the Durability of Infliximab Therapy in Children With Crohn's Disease
Victoria Grossi et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2015)
Benefits and Risks of Combining Anti-tumor Necrosis Factor with Immunomodulator Therapy in Pediatric Inflammatory Bowel Disease
Martinus A. Cozijnsen et al.
INFLAMMATORY BOWEL DISEASES (2015)
Monotherapy With Infliximab Versus Combination Therapy in the Maintenance of Clinical Remission in Children With Moderate to Severe Crohn Disease
Jaroslaw Kierkus et al.
JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION (2015)
The Danish National Patient Registry: a review of content, data quality, and research potential
Morten Schmidt et al.
CLINICAL EPIDEMIOLOGY (2015)
When the entire population is the sample: strengths and limitations in register-based epidemiology
Lau Caspar Thygesen et al.
EUROPEAN JOURNAL OF EPIDEMIOLOGY (2014)
The Danish Civil Registration System as a tool in epidemiology
Morten Schmidt et al.
EUROPEAN JOURNAL OF EPIDEMIOLOGY (2014)
A 10-Year, Single Tertiary Care Center Experience on the Durability of Infliximab in Pediatric Inflammatory Bowel Disease
Elaheh Vahabnezhad et al.
INFLAMMATORY BOWEL DISEASES (2014)
Infliximab Maintains Durable Response and Facilitates Catch-up Growth in Luminal Pediatric Crohn's Disease
Peter C. Church et al.
INFLAMMATORY BOWEL DISEASES (2014)
Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn's disease
F. M. Ruemmele et al.
JOURNAL OF CROHNS & COLITIS (2014)
Biological Therapy in a Pediatric Crohn Disease Population at a Referral Center
Federica Nuti et al.
JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION (2014)
Long-term outcome of tumor necrosis factor alpha antagonist's treatment in pediatric Crohn's disease
Amit Assa et al.
JOURNAL OF CROHNS & COLITIS (2013)
A British Society of Paediatric Gastroenterology, Hepatology and Nutrition survey of the effectiveness and safety of adalimumab in children with inflammatory bowel disease
R. K. Russell et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2011)
Epidemiology of Pediatric Inflammatory Bowel Disease: A Systematic Review of International Trends
Eric I. Benchimol et al.
INFLAMMATORY BOWEL DISEASES (2011)
Pediatric Modification of the Montreal Classification for Inflammatory Bowel Disease: The Paris Classification
Arie Levine et al.
INFLAMMATORY BOWEL DISEASES (2011)
The Danish National Prescription Registry
Helle Wallach Kildemoes et al.
SCANDINAVIAN JOURNAL OF PUBLIC HEALTH (2011)
The Danish National Patient Register
Elsebeth Lynge et al.
SCANDINAVIAN JOURNAL OF PUBLIC HEALTH (2011)
Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease.
Jean Frederic Colombel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Efficacy of Infliximab in Pediatric Crohn's Disease: A Randomized Multicenter Open-label Trial Comparing Scheduled to On Demand Maintenance Therapy
Frank M. Ruemmele et al.
INFLAMMATORY BOWEL DISEASES (2009)
Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children
Jeffrey Hyams et al.
GASTROENTEROLOGY (2007)
Share Paper
